Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.
Saved in:
| Title: | Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm. |
|---|---|
| Authors: | Raychaudhuri S; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Gooley TA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Rasmussen A; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Quach K; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Gill E; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Halpern AB; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Appelbaum JS; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Ghiuzeli CM; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Hendrie PC; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Walter RB; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA., Percival MM; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. |
| Source: | Blood neoplasia [Blood Neoplasia] 2025 Mar 03; Vol. 2 (3), pp. 100085. Date of Electronic Publication: 2025 Mar 03 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
